Search Results
Your search for The A matches 33029 pages
Showing 8001 - 8050Cleveland Clinic Launches Center for Young-Onset Colorectal Cancer
According to the National Cancer Institute, cases of colorectal cancer in patients younger than age 50 have grown by more than 50% since the 1990s. Cleveland Clinic has addressed this trend with the establishment of a center focused on the diagnosis, care, and research of young-onset colorectal...
Ruxolitinib for Chronic Graft-vs-Host Disease After Failure of Systemic Therapy
On September 22, 2021, ruxolitinib, a tyrosine kinase inhibitor of JAK1 and JAK2 was granted approval for treatment of chronic graft-vs-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients aged ≥ 12 years.1 Supporting Efficacy Data Approval was...
Advance Care Planning Is Crucial Component of Cancer Care
ASCO’s Coverage and Reimbursement Steering Group presented a poster on utilization of advance care planning (ACP) services at the ASCO Quality Care Symposium. The poster examined whether Current Procedural Terminology (CPT®) codes for ACP services are regularly utilized by hematology and oncology...
JCO OP Special Series: Disparities in Cancer Care for Hispanic-Latinx People
JCO Oncology Practice is now accepting manuscripts for a special issue on disparities in cancer care for Hispanic-Latinx people. Submit your manuscript today at https://www.editorialmanager.com/op-ascopubs/default.aspx Guest Editors Miguel Villalona-Calero, MD; Gilberto Lopes, MD, MBA; Narjust...
Noninferior Progression-Free Survival and Reduced Cardiovascular Toxicity With Acalabrutinib vs Ibrutinib in Previously Treated CLL
As reported in the Journal of Clinical Oncology by John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, and colleagues, the phase III ELEVATE-RR trial has shown noninferior progression-free survival with the more-selective Bruton’s tyrosine kinase (BTK) inhibitor...
Caroline Chung, MD, Named MD Anderson’s First Chief Data Officer
The University of Texas MD Anderson Cancer Center recently appointed Caroline Chung, MD, Associate Professor of Radiation Oncology and Diagnostic Radiology, the new Vice President and Chief Data Officer (CDO). As the institution’s first-ever CDO, Dr. Chung will be responsible for shaping MD...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bhutan
Located in the Eastern Himalayas, Bhutan is a landlocked, lower–middle-income country bordered by China and India. With a population of more than 850,000 people, Bhutan is predominately made up of three ethnic groups—the largest group is the Bhutia (also called Ngalop), followed by the Nepalese...
Cabozantinib for Previously Treated Advanced Differentiated Thyroid Cancer
On September 17, 2021, cabozantinib was approved for adult and pediatric patients aged ≥ 12 years with locally advanced or metastatic differentiated thyroid cancer progressing after VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.1 Cabozantinib inhibits the...
Urge Congress to Avoid Shutdown, Increase Funding for Cancer Research in Fiscal Year 2022
ASCO is calling on Congress to continue its bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets is critical in advancing our nation’s work toward...
Financial Impact of Cardiovascular Disease and Cancer Care: Overlapping Toxicities
The leading causes of mortality in the United States are cardiovascular disease (23%) and cancer (21%), accounting for more than 40% of total deaths reported.1,2 The increasing rise in health-care expenditures over the past several decades has driven the need for metrics to further evaluate the...
Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer
On September 20, 2021, tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, was granted accelerated approval for the treatment of adults with recurrent or metastatic cervical cancer who have had disease progression on or after chemotherapy.1 Supporting...
Financial Toxicity Associated With Atherosclerotic Cardiovascular Disease, Cancer, and Both in U.S. Adult Patients
In a study of National Health Interview Survey (NHIS) data reported in JACC: CardioOncology, Javier Valero-Elizondo, MD, MPH, of Houston Methodist DeBakey Heart and Vascular Center, and colleagues, found that U.S. adult patients aged 18 to < 65 years with atherosclerotic cardiovascular disease...
Expert Point of View: Bruna Pellini, MD
Study discussant Bruna Pellini, MD, of the Department of Thoracic Oncology, Moffitt Cancer Center, Florida, noted that, regardless of PD-L1 or tumor mutation burden status, the NADIM trial demonstrated improved progression-free and overall survival for patients with resectable, stage IIIA non–small ...
Pretreatment Levels of Circulating Tumor DNA May Predict Long-Term Survival in NSCLC
Pretreatment circulating tumor DNA (ctDNA) levels in patients with non–small cell lung cancer (NSCLC) appear to be a more accurate predictor of long-term survival than classic survival surrogates, according to research presented during the International Association for the Study of Lung Cancer...
Expert Point of View: Julie Brahmer, MD, MSc, FASCO
Discussant of the POSEIDON trial, Julie Brahmer, MD, MSc, FASCO, Co-Director of the Upper Aerodigestive Department within the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Medicine, applauded the numerous treatment choices now available to patients with metastatic non–small...
POSEIDON Trial: Dual Checkpoint Blockade Plus Chemotherapy Improves Survival in First-Line Metastatic NSCLC
The combination of dual checkpoint inhibition plus chemotherapy could be the new standard of care in first-line metastatic non–small cell lung cancer (NSCLC), according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer.1 ...
Expert Point of View: Heather A. Wakelee, MD, FASCO, and Erika Hlavacek
Heather A. Wakelee, MD, FASCO, President of the International Association for the Study of Lung Cancer (IASLC), who moderated a press briefing where the results of the Atezo-Brain trial were presented, called the study “beautiful work designed specifically” for patients with non–small cell lung...
Phase II Trial Finds Atezolizumab of Benefit in Patients With Lung Cancer and Brain Metastases
Patients with non–small cell lung cancer (NSCLC) and brain metastasis derived significant benefit from treatment with the monoclonal antibody atezolizumab plus chemotherapy, according to the multicenter phase II Atezo-Brain trial.1 The study was presented at the International Association for the...
MSK Announces Appointment of Deb Schrag, MD, FASCO, MPH, as Chair of the Department of Medicine
Deb Schrag, MD, FASCO, MPH, has been named the new Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Dr. Schrag has a deep familiarity with MSK, having previously spent 8 years at the institution as a physician and faculty member. She joins MSK from the...
Expert Point of View: J. Kellogg Parsons, MD, MHS, FACS
“Population-based screening for prostate cancer reduces prostate cancer mortality,” noted J. Kellogg Parsons, MD, MHS, FACS, Professor of Urology, UC San Diego Health, who commented on the study. “Effective screening programs focus on the early detection of aggressive but curable tumors, minimize...
IASLC Names Kristin Richeimer, CAE, DES, Interim Chief Executive Officer
The Board of Directors of the International Association for the Study of Lung Cancer (IASLC) has announced the appointment of Kristin Richeimer, CAE, DES, to the position of Interim Chief Executive Officer (CEO). Ms. Richeimer joined the IASLC in 2010 as its first Director of Membership and brings ...
Michael Diaz, MD, Named President and Managing Physician at Florida Cancer Specialists & Research Institute
Florida Cancer Specialists & Research Institute (FCS) recently appointed Michael Diaz, MD, to the position of President and Managing Physician, effective January 1, 2022. Dr. Diaz succeeds Lucio Gordan, MD, who has served in that position since 2018. Dr. Gordan will continue to practice as a...
Expert Point of View: Eleni Efstathiou, MD
Invited discussant Eleni Efstathiou, MD, of Houston Methodist Cancer Center and Athens Medical Center, Greece, said that both the STAMPEDE meta-analysis1 and the PEACE-1 trial2 firmly establish the importance of introducing abiraterone acetate earlier in the course of treatment. “The STAMPEDE...
Jenny Jing Xiang, MD, on Improving Clinical Trial Recruitment With a Universal Prescreening Protocol
Jenny Jing Xiang, MD, of Yale University School of Medicine, discusses a universal, standardized clinical trial prescreening protocol, which streamlined research recruitment and was associated with yearly increases in patient enrollment at the Veterans Administration (VA) Connecticut Cancer Center. ...
STAMPEDE: In Nonmetastatic Castration-Sensitive Prostate Cancer, Abiraterone Added to Androgen-Deprivation Therapy Improves Survival
The addition of 2 years of abiraterone acetate plus prednisolone (AAP) to androgen-deprivation therapy improves metastasis-free survival and overall survival compared with androgen-deprivation therapy alone in men with nonmetastatic castration-sensitive prostate cancer, according to a primary...
Expert Point of View: Florian Lordick, MD, PhD
Florian Lordick, MD, PhD, Professor of Oncology and Director of the University Cancer Center Leipzig, Germany, applauded the positive finding for nivolumab plus chemotherapy in CheckMate 6491 and questioned why nivolumab plus ipilimumab did not meet its endpoint. “I’m calling this a big step...
CheckMate 649: Long-Term Data Support Nivolumab Plus Chemotherapy but Not Nivolumab Plus Ipilimumab in Gastric Cancer
Longer follow-up data from the phase III CheckMate 649 trial support the use of nivolumab plus chemotherapy as a new standard first-line regimen in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The findings were reported by Yelena Janjigian, ...
Expert Point of View: Omid Hamid, MD
Commenting on the SECOMBIT trial was Omid Hamid, MD, Chief of Translational Research and Immunotherapy at The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate, and Co-Director, Cutaneous Malignancy Program, Cedars-Sinai Cancer. Dr. Hamid said SECOMBIT addresses an important...
St. Jude Names Shannon Dean, MD, as Chief Medical Information Officer
Shannon Dean, MD, has joined St. Jude Children’s Research Hospital as Chief Medical Information Officer at a key time in the hospital’s efforts to enhance the patient experience. Dr. Dean will help oversee the launch of the hospital’s new electronic health record, which is scheduled to go live in...
SECOMBIT Trial Evaluates Optimal Treatment Sequencing in BRAF-Mutated Melanoma
Patients with untreated, metastatic BRAF-mutated melanoma may benefit from receiving immunotherapy first, moving to targeted therapy in the second line, data from the updated overall survival analysis of the randomized, phase II SECOMBIT trial suggest.1 The study aimed to define the optimal...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, of the Breast Cancer Group at Gustave Roussy Cancer Center, Villejuif, France, said the results of the TULIP trial, showing the progression-free survival benefit for vic-trastuzumab duocarmazine (SYD985), help to establish antibody-drug conjugates as key components of the...
Another Antibody-Drug Conjugate Enters the Metastatic Breast Cancer Landscape
In the global phase III TULIP trial in metastatic HER2-positive breast cancer, treatment with the antibody-drug conjugate vic-trastuzumab duocarmazine (SYD985) significantly improved progression-free survival in comparison with standard chemotherapy in previously treated patients, making this a new ...
Expert Point of View: Enrique Grande, MD
Invited discussant Enrique Grande, MD, of the Medical Oncology Department at MD Anderson Cancer Center Madrid, said that the VESPER trial should really be regarded as a neoadjuvant trial, since 88% of the patients enrolled were treated in the neoadjuvant setting. He focused the rest of his remarks ...
Neoadjuvant dd-MVAC Improves Local Control and Progression-Free Survival in Patients With Muscle-Invasive Bladder Cancer
The VESPER phase III trial answers some key questions regarding the optimal management of muscle-invasive bladder cancer. The study found that the neoadjuvant regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) was superior to standard gemcitabine/cisplatin in...
Expert Point of View: Johnie Rose, MD, PhD
Invited study discussant, Johnie Rose, MD, PhD, noted that screening is a complex problem that requires balancing the risks of avoidable metastatic prostate cancer with the serious complications associated with treatment. Dr. Rose is Assistant Professor at the Center for Community Health...
Did Change in PSA-Based Screening Recommendation Hinder Prostate Cancer–Specific Survival?
Prostate-specific antigen (PSA) screening recommendations made by the U.S. Preventive Services Task Force (USPSTF) in 2012 may have led to worse outcomes for insured patients with prostate cancer, according to data presented at the 2021 ASCO Quality Care Symposium.1 Findings from the retrospective...
Study Assesses Benefit of Digital Health Tools for Cancer Survivors
New study results suggest that to maximize effects of digital support tools for cancer survivors, it is essential to personalize information and increase engagement efforts. The report, published by Leach et al in the journal Cancer, demonstrated significant improvement in the ability to manage...
Two Studies Examine the Efficacy of Immunotherapy for Leptomeningeal Carcinomatosis
Two new studies published in Nature Communications indicate that immunotherapy may benefit people with leptomeningeal carcinomatosis, a rare but serious complication of cancer that has spread to the brain and/or spinal cord. Approximately 5% to 8% of all patients with cancer develop leptomeningeal ...
National Cancer Act and Lung Cancer Screening: An Example of Intended Impact
The National Cancer Act of 1971 established a national priority to address the widely shared dread of a cancer diagnosis. The goal of the National Cancer Act was to strengthen the National Cancer Institute (NCI) to more effectively carry out the national effort against cancer. After the Act was...
BTK Inhibition in CLL: An Embarrassment of Riches
Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder defined by a specific phenotype and the presence of more than 5,000 clonal B cells in the peripheral blood.1 In the absence of this number of circulating cells, its soft-tissue/bone-marrow counterpart is semantically...
Expert Point of View: Gonzalo Gomez-Abuin, MD, and Gabriel N. Hortobagyi, MD, MACP, FASCO
The invited discussant of the MONALESSA-2 trial was Gonzalo Gomez-Abuin, MD, a medical oncologist who is Head of the Clinical Research Unit at Hospital Alemán in Buenos Aires. According to Dr. Gomez-Abuin, phase III trials of three different CDK4/6 inhibitors—ribociclib, palbociclib, and...
MONALEESA-2: Overall Survival Benefit With First-Line Ribociclib Plus Letrozole
Ribociclib plus hormonal therapy in the first-line setting boosted overall survival by more than 1 year, vs hormone therapy alone, in postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer, according to the latest findings from the MONALEESA-2 trial, reported at...
Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, and colleagues, an interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to lenalidomide/dexamethasone in newly diagnosed, transplant-ineligible patients with ...
Addition of Liposomal Irinotecan to Fluorouracil and Leucovorin as Second-Line Treatment for Metastatic Biliary Tract Cancer
In a Korean phase IIb trial (NIFTY) reported in The Lancet Oncology, Yoo et al found that the addition of liposomal irinotecan to fluorouracil/leucovorin improved progression-free survival as a second-line treatment for patients with metastatic biliary tract cancer whose disease had progressed on...
Risk-Based Treatment of Pediatric and Young Adult Synovial Sarcoma
In a report from the Children’s Oncology Group ARST0332 study published in the Journal of Clinical Oncology, Venkatamani et al found that risk-based treatment of pediatric and young adult patients with synovial sarcoma produced favorable outcomes in those with nonmetastatic disease. Outcomes in...
Expert Point of View: Joshua K. Sabari, MD
“We know that molecular alterations on gene mutations such as EGFR and ALK can lead to better prognosis, better response rates, and, more important, better quality of life for patients,” said Joshua K. Sabari, MD, of NYU Langone Health Perlmutter Cancer Center, who discussed the abstract at the...
Survey Shows Disparities in Biomarker Testing Among Underserved Patients With Lung Cancer
Recent advances in cancer genomics and targeted therapies have changed the treatment landscape for lung cancer, but disparities in access to precision medicine remain, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung ...
Activity of Nab-sirolimus in Malignant Perivascular Epithelioid Cell Tumors
In the phase II AMPECT trial reported in the Journal of Clinical Oncology, Wagner et al found that the mTOR inhibitor nab-sirolimus produced a substantial rate of durable responses and a high disease control rate in patients with malignant perivascular epithelioid cell tumors. As stated by the...
Development of a Breast Cancer Risk Prediction Model for Black Women in the United States
As reported in the Journal of Clinical Oncology, Julie R. Palmer, ScD, and colleagues have developed and validated a risk prediction model for invasive breast cancer in Black women in the United States. Study Details For the development of the model, breast cancer relative and attributable risks...
Pharmacovigilance Study of Pancytopenia in Patients Receiving PARP Inhibitors
In a study reported in a research letter in JAMA Oncology, Morice et al found that pancytopenia was associated with use of poly (ADP-ribose) polymerase (PARP) inhibitors for cancer treatment, according to drug adverse event reports in the World Health Organization global pharmacovigilance database...
